Clarivate Plc, a leading global provider of transformative intelligence, has unveiled its new OFF-X™ platform, designed to revolutionize preclinical and clinical safety intelligence. The enhanced platform promises a seamless user experience and unique translational insights, delivering critical drug and target safety intelligence to proactively identify risks. Fully integrated with Cortellis Drug Discovery Intelligence™, OFF-X™ stands as a comprehensive, one-stop resource for safety information, streamlining processes and enhancing efficiency for a competitive edge.
The new OFF-X™ platform features an upgraded technology stack and enhanced functionality, retaining its core capabilities while introducing significant improvements. Users will benefit from an 80% reduction in loading times for targets, drugs, drug combinations, and adverse events. The platform also boasts faster search capabilities, a clearer visual design, full-screen visualization, and additional analytic tools.
These enhancements empower users to monitor and anticipate toxicology and safety signals, mitigate safety liabilities, and de-risk assets across all phases of drug research and development (R&D) and post-marketing. This robust platform supports confident development and investment decisions, underscoring Clarivate's commitment to advancing the field of drug safety intelligence.
Click here to read the original press release.
